Zalifrelimab

Balstilimab plus zalifrelimab demonstrated promising and durable activity among women with recurrent and/or metastatic cervical cancer who relapsed after platinum-based therapy, according to a phase 2 study in Journal of Clinical Oncology.

The FDA granted fast track designation to balstilimab for treatment of women with advanced cervical cancer.

The FDA granted fast track designation to balstilimab in combination with zalifrelimab for the treatment of women with relapsed or refractory metastatic cervical cancer, according to the agents’ manufacturer.